Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maolactin FMR for Inflammation and Muscle Comfort
NCT06444763Phase 3Completed
- Sponsor
- RDC Clinical
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammation, myalgia and arthralgia, sponsored by RDC Clinical. Primary endpoint: Change in Inflammatory status at 8 weeks. Started Feb 2025; status: completed.
02
Conditions
chronic inflammationmyalgiaarthralgia
Beyond the preview
Go deeper on NCT06444763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444763.